Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,594
  • Shares Outstanding, K 130,465
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,170 K
  • EBIT $ -103 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.70
  • Most Recent Earnings $-0.12 on 02/26/26
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 338.34% (+156.31%)
  • Historical Volatility 103.19%
  • IV Percentile 63%
  • IV Rank 38.57%
  • IV High 773.64% on 10/21/25
  • IV Low 65.03% on 10/20/25
  • Expected Move (DTE 24) 0.2890 (30.84%)
  • Put/Call Vol Ratio 3.33
  • Today's Volume 117
  • Volume Avg (30-Day) 228
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 8,506
  • Open Int (30-Day) 18,094
  • Expected Range 0.6480 to 1.2260

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 7
  • High Estimate $-0.05
  • Low Estimate $-0.20
  • Prior Year $-0.25
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9200 +1.08%
on 04/20/26
1.3500 -31.12%
on 03/25/26
-0.1701 (-15.46%)
since 03/20/26
3-Month
0.5727 +62.37%
on 02/05/26
1.5100 -38.42%
on 03/12/26
+0.2706 (+41.04%)
since 01/21/26
52-Week
0.5062 +83.70%
on 12/30/25
1.5100 -38.42%
on 03/12/26
-0.0592 (-5.99%)
since 04/21/25

Most Recent Stories

More News
Immunic to Participate in Scientific and Medical Conferences in April

NEW YORK , April 9, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

IMUX : 0.9389 (-1.69%)
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK , April 1, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX) ,  a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...

IMUX : 0.9389 (-1.69%)
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –

IMUX : 0.9389 (-1.69%)
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –

IMUX : 0.9389 (-1.69%)
Immunic to Participate in Investor Conferences in March

NEW YORK , March 3, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 0.9389 (-1.69%)
Immunic: Q4 Earnings Snapshot

Immunic: Q4 Earnings Snapshot

IMUX : 0.9389 (-1.69%)
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –

IMUX : 0.9389 (-1.69%)
Immunic Announces Closing of Oversubscribed Private Placement Financing

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 0.9389 (-1.69%)
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –

IMUX : 0.9389 (-1.69%)
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –

IMUX : 0.9389 (-1.69%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.0867
2nd Resistance Point 1.0463
1st Resistance Point 1.0007
Last Price 0.9389
1st Support Level 0.9147
2nd Support Level 0.8743
3rd Support Level 0.8287

See More

52-Week High 1.5100
Fibonacci 61.8% 1.1265
Fibonacci 50% 1.0081
Last Price 0.9389
Fibonacci 38.2% 0.8897
52-Week Low 0.5062

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.